CELL INTELLIGENCE · 肿瘤细胞治疗研究

HER2 治疗膀胱癌、头颈部鳞癌：I 期临床试验（Baylor College of）

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

这是一项 I 期注册临床试验，评估细胞治疗用于膀胱癌、头颈部鳞癌、恶性肿瘤的安全性、可行性及初步疗效。当前状态：招募中。计划入组 45 例。试验地点：美国 · 休斯顿（共 1 个中心）。登记号：NCT03740256。

晚期 HER2 阴性乳腺癌患者瘤内注射 talimogene laherparepvec（T-VEC）联合化疗或内分泌治疗的 Ib 期研究

Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-n

溶瘤腺病毒免疫治疗增强同种异体过继 HER2.CAR-NK 抗胰腺导管腺癌功能

Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma.

乳腺癌免疫治疗：超越免疫检查点抑制剂

Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors.

编码 IL-12 的 oNDV 与 CAR-T 细胞在非小细胞肺癌原位模型中的协同作用

IL-12 encoding oNDV synergizes with CAR-T cells in orthotopic models of non-small cell lung cancer.

CAR-T 细胞与溶瘤病毒疗法治疗胃癌及胃癌源性腹膜癌病：改善联合策略之路

Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving C